



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Gerlinde LENZEN, et al.) Group Art Unit: 1646
Serial No.: 09/319,724) Examiner: Brannock, M.T.
Filed: September 8, 1999)
Title: MAMMALIAN ICYP(ODO -)
CYANOPINDOLOL RECEPTOR)
AND ITS APPLICATIONS)

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, 1B03
Arlington, VA 22202

RECEIVED
FEB 03 2004
TECH CENTER 1001

Sir:

Pursuant to 37 C.F.R. 1.97(e)(1), applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449, which were cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration of relevant portions thereof by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17

which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN LEWIS & BOCKIUS LLP

By 
Bonnie Weiss McLeod
Reg. No. 43,255

Dated: January 29, 2004

Customer No. 09629

1111 Pennsylvania Avenue, N.W.


Washington, D.C. 20004

Phone: (202) 739-3000

Facsimile: (202) 739-3001

Direct: (202) 739-6150

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

053356-5001-US

532415MS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: LENZEN ET AL

Appln. No.: 09/319,724

Filing Date: September 8, 1999

Date: January 27, 2004

Page

1

of

1

Examiner: Brannock

Group Art Unit: 1646

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					
	HR					
	IR					

RECEIVED
FEB 03 2004
TECH CENTER 1600/2

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclose	No
	JR									
	KR									
	LR									
	MR									
	NR									
	OR									
	PR									
	QR									
	RR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

SR	Sugasawa et al, J. Biol. Chem., 272(34):21244-21252 (August, 1997)	X		
TR	Strosberg et al, Trends Pharm. Sci., 17:373-381 (October, 1996)	X		
UR				
VR				
WR				
XR				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.